Boston Scientific Corporation (BSX)
BSX trades on NYSE in Health Care, Medical/Dental Instruments. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/885725/000088572526000010/0000885725-26-000010-index.htm. Net income: SEC 10-K (us-gaap:ProfitLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | BSX on NYSE |
| Sector | Health Care |
| Industry | Medical/Dental Instruments |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000885725 |
| SEC industry code | Surgical & Medical Instruments & Apparatus |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $20.1B |
| Net income | $2.9B |
| Operating income | $3.6B |
| Net margin | 14.4% |
| Operating margin | 18.0% |
| Revenue growth | +19.9% |
| Cash | $2.0B |
| Total assets | $43.7B |
| P/E (computed) | 21.9× |
| P/S (computed) | 3.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-02 |
| Cash and burn | $609.0M cash; operating cash flow $1.1B a quarter. | Report 2026-09-30 |
| Shares outstanding | 1,449,473,222 (2026-10-29); 1,482,442,039 a year earlier; 1,464,982,777 three years earlier. | Cover page 2026-10-29 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $10.0M, sold $29.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $5.1B | $580.0M | $1.0B | $609.0M | $12.0B | $21.1B | 10-Q 2026-11-02 |
| Q2 2026 2026-06-30 | $5.4B | $905.0M | $1.5B | $539.0M | $12.6B | $21.0B | 10-Q 2026-08-03 |
| Q1 2026 2026-03-31 | $5.2B | $1.3B | $348.0M | $1.5B | $11.0B | $20.6B | 10-Q 2026-05-01 |
| Q4 2025 2025-12-31 | $5.3B | $670.0M | $1.4B | $2.0B | $11.4B | $20.1B | 10-K 2026-02-17 |
| Q3 2025 2025-09-30 | $5.1B | $755.0M | $1.3B | $1.3B | $11.6B | $19.4B | 10-Q 2026-11-02 |
| Q2 2025 2025-06-30 | $5.1B | $795.0M | $1.3B | $534.0M | $11.6B | $18.5B | 10-Q 2026-08-03 |
| Q1 2025 2025-03-31 | $4.7B | $672.0M | $541.0M | $725.0M | $11.3B | $17.6B | 10-Q 2026-05-01 |
| Q4 2024 2024-12-31 | $4.6B | $562.0M | $1.5B | $414.0M | $10.7B | $16.7B | 10-K 2026-02-17 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B3 | 2026-04-01 |
| Latest annual report | 10-K | 2026-02-17 |
| Latest quarterly / interim | 10-Q | 2026-11-02 |
| Latest current report | 8-K | 2026-10-28 |
| Latest proxy | DEFA14A | 2026-03-18 |
Source: SEC EDGAR submissions feed, 1,003 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +3.7% |
| 1 month | +2.4% |
| 3 months | -14.2% |
| Year to date | -53.5% |
| 1 year | -57.8% |
| From 52-week high | -56.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Medical/Dental Instruments
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BDX | Becton Dickinson and Company | $216.47 | -0.72% | $59.0B |
| MDLN | Medline Inc. | $39.17 | -0.76% | $51.5B |
| MMM | 3M Company | $181.68 | -1.08% | $93.9B |
| SYK | Stryker Corporation | $310.72 | +0.35% | $118.3B |
| RMD | ResMed Inc. | $238.19 | -0.56% | $33.5B |
| DXCM | DexCom Inc. | $81.61 | -2.06% | $30.4B |
| WST | West Pharmaceutical Services Inc. | $417.80 | +0.33% | $29.1B |
| SOLV | Solventum Corporation | $88.65 | -0.48% | $15.0B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier